Capecitabine plus bevacizumab versus capecitabine in maintenance treatment for untreated characterised KRAS exon 2 wild-type metastatic colorectal cancer: a retrospective analysis in Chinese postmenopausal women

BACKGROUND: Capecitabine plus bevacizumab (CAP-B) maintenance treatment after 6 cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOXB) has demonstrated clinical activity and failure to compromise quality of life in patients with metastatic colorectal cancer (MCC) in a previous phase 3 CAIRO3...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Jinsong, Lai, Jiajie, Yang, Ruikun, Xu, Bo, Zhu, Ying, Zhao, Mingdong, Yang, Chen, Liang, Guanzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346504/
https://www.ncbi.nlm.nih.gov/pubmed/30683047
http://dx.doi.org/10.1186/s12876-018-0916-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346504/
https://www.ncbi.nlm.nih.gov/pubmed/30683047
http://dx.doi.org/10.1186/s12876-018-0916-6

Ejemplares similares